Progenra
  • About
    • Investor Relations
    • Leadership
  • Covid-19 Therapeutics
  • Therapeutic Focus
    • The Ubiquitin Proteasome System (UPS)
    • UbiPro™ Platform
    • PROTAC Platform
    • Therapeutic Areas
  • Partnering
    • The Progenra Advantage
    • Partnering Opportunities
    • Collaborations
  • Careers
    • R&D, Biology
    • R&D, Medicinal Chemistry
  • News
    • News
    • Meetings
    • Publications
  • Blog
Select Page

Progenra Inc. Receives Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research and Drug Development

by admin | Dec 14, 2018 | News

Funding will support Progenra’s development of small molecules for treatment of Parkinson’s Disease Malvern, PA (Dec 8, 2018) – Progenra Inc. announces the receipt of a 2018 Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)....

Recent Posts

  • Progenra receives funding from the Michael J Fox Foundation to develop Parkin activators to treat Parkinson’s disease.
  • Progenra Scientists publish a chapter in the ACS 2019 Medicinal Chemistry Reviews.
  • Characterization of Selective Covalent inhibitors of USP7- AACR Poster
  • Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
  • Immune Regulation by Protein Ubiquitination: Roles of the E3 Ligases VHL and Itch

Archives

  • May 2020
  • May 2019
  • December 2018
  • April 2018
  • March 2018
  • September 2017
  • June 2017
  • May 2017
  • December 2016
  • December 2015
Progenra Logo

Contact

  610.644.6974
  610.644.8616
   271A Great Valley Parkway
      Malvern PA, 19355

For More Information

  info@progenra.com
  bd@progenra.com
      (Business Development inquries)
  • Facebook
  • Twitter
  • LinkedIn
© 2022 Progenra Inc. All Rights Reserved.
Website Designed by eNet Web Services